ServiziMenu principaleHome
You are here: Home > WOF > Past editions > WOF 2017

WOF 2017

Facebook  Twitter  Linkedin  You Tube

 WOF 2017


  Thursday, 19 October 2017

    Arrivals (Late afternoon)              
 19:00   Introductory keynote lecture
F. Bray (Lyon, FR): Global burden of cancer and new challenges
 20:00   Dinner (Salone del Camino)
 Friday, 20 October 2017

  8:45   F. Cavalli (Bellinzona, CH): Remembering Prof. U. Veronesi
  8:50   F. Cavalli (Bellinzona, CH): What do we want to achieve with this WOF?
9:00-10:45 Cancer control and health care agenda: old problems, new possibilities      
                  Chairpersons: M. Gospodarowicz (Toronto, CA), A. Eggermont (Villejuif, FR)
 M. Uhlén (Stockholm, SE): New possibilities for better prevention and early diagnosis offered by basic research -
 More basic aspects

   M. Jamal-Hanjani (London, UK): New possibilities for better prevention and early diagnosis - Clinical aspects

   D. Milner (Chicago, US): Central role of modern pathology realizing cancer control

   R. Sullivan (London, UK): Structural improvement for delivering local therapies: the basis

   T. Fojo (New York, US): Which role for “new systemic treatments”?
  N. Magrini (Geneva, CH): The list of essential medicines of WHO
 11:00   Coffee break
 11:15   Round table and general discussion
Moderators:  F. Cavalli (Bellinzona, CH), R. Sullivan (London, UK)
Round table participants: C. Booth (Kingston, CA), P. Workman (London, UK), C. Galindo (Memphis, US)
 12:45   Lunch (Restaurant Le Relais)
14:00-15:45 How to measure the progress, if any, in the global fight against cancer?
                   Chairpersons: C. Stefan (Cape Town, ZA), S. Aranda (Melbourne, AU)
    Overview on different situations:
   Middle East, Princess Dina Mired (Amman, JO)

   China, Y.L. Qiao (Beijing, CN)

   Latin America, A. Mohar (Mexico City, MX)

   Africa, HMH I. Adewole, (Abuja, NG)

   General picture, R. Laxminarayan (Washington DC, US) / E. Trimble (Bethesda, US)
  Coffee break (Salone del Camino)
 16:15   R. Yates (London, UK): Why Universal Health coverage must include oncology services
  S. Aranda (Melbourne, AU): Cities Project
 16:55   F. Knaul (Miami, US) / M. Gospodarowicz (Toronto, CA): Diagonal approach
 17:15   Round table and general discussion
Moderators: F. Bray (Lyon, FR) and E. Trimble (Bethesda, US)
Round table participants: C.S. Pramesh (Mumbai, IN), N. Enwerem-Bromson (Vienna, AT), F. Colombo (Paris, FR) 

 18:30   End daily programme
 20:00   Cocktails (Salone del Camino)
 20:30   Dinner (Restaurant Arté al Lago)
 Saturday, 21 October 2017


Final Session
Chairperson: T. Zeltner (Bern, CH)


Keynote lecture
R. Atun (Boston, US): How to fund cancer control globally

 9:30   Round table and discussion about different models for funding cancer control
Moderator: T. Zeltner (Bern, CH)
Round table participants: P. Wennubst (Bern, CH), R. Atun (Boston, US), R. Yates (London, UK), M. Gospodarowicz (Toronto, CA)

10:30   Coffee break (Salone del Camino)
11:00   Final discussion about implementation of decisions/proposals
Chairpersons: F. Cavalli (Bellinzona, CH), R. Atun (Boston, US)
12:00   Close



Sanchia Aranda, Cancer Council Australia, Australia
Rifat Atun, Harvard University, USA
David Atuwo, Federal Ministry of Health Nigeria, Nigeria
Christopher Booth, Queen’s University, Canada
Riccardo Braglia, Helsinn Healthcare SA, Switerland
Otis Brawley, American Cancer Society, USA
Freddie Bray, International Agency for Research on Cancer, France
Hermann Brenner, German Cancer Research Center, Germany
Felipe A. Calvo Manuel, General University Hospital Gregorio MaraÑon, Spain
Franco Cavalli, European School of Oncology, Switzerland
Thomas Cerny, HCARE-KSSG-ONKO, Switzerland
Francesca Colombo, OECD, France
Alberto Costa, European School of Oncology, Italy and Switzerland
Amadou Diarra, Bristol-Meyers Squibb, USA
Patrick Durisch, Public Eye, Switzerland
Alexander M.M. Eggermont, Gustave Roussy Cancer Campus Grand Paris, France
Aleandru Eniu, Cancer Institute “Ion Chiricuta”, Romania
Nelly Enwerem-Bromson, International Atomic Energy Agency (IAEA), Austria
Sabine Flessenkaemper, German International Cooperation (GIZ), Germany
Antonio Tito Fojo, Columbia University, USA
Joxel Garcia, American Express, USA
Livia Giordano, S. Giovanni Battista Hospital and Turin University, Italy
Mary K. Gospodarowicz, Princess Margaret Cancer Center – University of Toronto, Canada
Anton Hagenbeek, Academic Medical Centre, The Netherlands
Marjo Hahka Kemppinen, Lilly International, Finland
Xishan Hao, Chinese Anti-Cancer Association, China
E. Blair Holladay, American Society for Clinical Pathology, USA
André Ilbawi, World Health Organization, Switzerland
Mariam Jamal-Hanjani, UCL Cancer Institute and UCL Hospitals, United Kingdom
Jose Jeronimo, Global Coalition Against Cervical Cancer (GC3), USA
Sharon Kapambwe, Ministry of Health/Centre for Infectious Disease Research in Zambia, Zambia
Stan Kaye, The Institute of Cancer Research, The Royal Marsden Hospital, UK
David Kerr, Oxford University, UK
Harpal Kumar, Cancer Research UK, UK
Augustin Lage, Center of Molecular Immunology (CIM), Cuba
Anne Wing Mui Lee, The University of Hong Kong, Hong Kong
Nicola Magrini, World Health Organization, Switzerland
Grazia Marcianesi Casadei, Italian Development Cooperation (AICS), Italy
Giorgio Massimini, Merck KGaA, Germany
Danny Milner, American Society for Clinical Pathology, USA
HRH Princess Dina Mired, Union for International Cancer Control, Jordan
Alejandro Mohar Betancourt, National Cancer Institute, Mexico
Fedro Peccatori, European School of Oncology, Italy
Dinesh Pendharkar, Asian Cancer Institute, India
Erika Placella, Swiss Agency for Development and Cooperation (SDC), Switzerland
Philip Poortmans, Instiut Curie, France
C.S. Pramesh, Tata Memorial Centre, India
You-Lin Qiao, National Cancer Center, China
Carlos Rodriguez-Galindo, St. Jude Children’s Hospital, USA
Luiz Santini, Red de Institutos Nactionales de Cancer de Sudamerica, Brazil
Peter Selby, University of Leeds, UK
Lena Sharp, Regional Cancer Centre, Stockholm-Gotland, Sweden
Lan-Lan Smith, The Lancet Haematology, UK
Cristina Stefan, African Medical Research and Innovation Institute (AMRII), South Africa
Richard Sullivan, King’s Comprehensive Cancer Centre, UK
Edward Trimble, US National Cancer Institute, USA
Mathias Uhlen, KTH Royal Institute of Technology, Sweden
Peter Varnum, World Economic Forum, Switzerland
Paolo Veronesi
, European Institute of Oncology, Italy

Pio Wennubst, Swiss Agency for Development and Cooperation, Switzerland
Beatrice Wiafe Addai, Breast Care International/Peace and Love Hospitals, Ghana
Paul Workman, The Institute of Cancer Research, UK
Robert Yates, Chatham House, UK
Thomas Zeltner, Swiss Academy of Medical Sciences, Switzerland


Fabrizio Barazzoni, Ente Ospedaliero Cantonale, Switzerland
Jean-Yves Douillard, European Society for Medical Oncology (ESMO), Switzerland
Cristina Ferrario, Agenzia Zoe and Cancer World Magazine, Italy
Nelido Gonzalez, National Institute of Oncology and Radiobiology, Cuba
Peter McIntyre, Oxford, UK
Giorgio Noseda, Switzerland
Diana Romero, Springer Nature, UK

Titta Rosvall-Puplett, All.Can, Belgium
Luciano Ruggia
, Institute of Social and Preventive Medicine, Switzerland
Piercarlo Saletti
, Oncology Institute of Southern Switzerland, Switzerland
Diana Sarfati
, University of Otago, New Zealand

Susana Stanway, Royal Marsden Hospital, UK
Anna Wagstaff, Cancer World Magazine, UK


  Is a global movement to tackle cancer possible?
Author: Peter McIntyre
CancerWorld Magazine Webiste (31 October 2017) / European School of Oncology (ESO)
  A is for apple (but not always in Africa)
Author: Cristina Ferrario
CancerWorld Magazine Webiste (26 October 2017) / European School of Oncology (ESO)
  The (overrated) power of the hazard ratio
Author: Cristina Ferrario
CancerWorld Magazine Webiste (24 October 2017) / European School of Oncology (ESO)

  The global fight against cancer: challenges and opportunities
Rifat Atun, Franco Cavalli
www.thelancet.com - Vol 391 - February 3, 2018



  Highlights of the World Oncology Forum (WOF) - Cancer and global health: from research to policy
E-session 419
  WOF 2017 Overview
“Can global barriers to meeting the cancer challenge be overcome?”
  Franco Cavalli: «Policy makers must be more engaged in the fight against cancer»
The World Oncology Forum in Lugano, Switzerland, in October set a global challenge to address the growing threat from cancer in middle and low income countries. In the first of a series of short videos, WOF chair Franco Cavalli, explains what the Forum is seeking to do.
  Freddie Bray: «Four in five countries cannot accurately report cancer deaths»
Countries across the world need to prepare for a 60% rise in cancer cases over the next two decades. Freddie Bray Head of Cancer Surveillance at the International Agency for Research on Cancer (IARC) told the World Oncology Forum in Lugano that countries need better data if they are to plan more effective action.
  Rifat Atun: Seven point strategy to tackle global cancer
Rifat Atun, Director of Global Health Systems at Harvard, warns the cancer community they must heal fragmented delivery and financing systems to tackle cancer worldwide. He summarises a seven point strategy from the World Oncology Forum to boost innovation and service delivery and to achieve impact at scale.
  Mary Gospodarowicz: «We need a ‘can-do’ attitude to global cancer control»
I absolutely hate the assumption that cancer is too complicated for us to act. In fact probably cancer care and control is much less complicated than running the infrastructure in Mumbai, or London or Manhattan.
  Princess Dina Mired: «Support developing countries to make cancer control plans»
Princess Dina Mired of Jordan is calling on the international cancer community to change the way it supports low- and middle-income countries to combat cancer. International support must start from the needs and priorities of the country and help to create achievable action plans.
  Richard Sullivan: «How about a 5% levy on research to boost global cancer aid?»
High-income countries need to target cancer when allocating health care funds to emerging and low income countries, says Richard Sullivan, Professor of Cancer and Global Health at Kings College London. He proposes that those funding research programmes in richer countries should pay a 5% donations levy to support cancer services in the developing world.
  Sharon Kapambwe: Meet the team, not just the Minister to support cancer strategies
Global cancer programmes and projects must pay greater attention to national priorities and structures when they offer support to developing countries, says the doctor responsible for efforts to reduce women’s cancer in Zambia.
  Tito Fojo: Cancer drugs not delivering on their potential
New drugs being approved for treatment of patients with cancer are providing an average of only 2.5 months of extra life, a leading researcher has told the World Oncology Forum (WOF). Tito Fojo, Professor of Medicine at Columbia University, New York, and a former principal investigator for the National Cancer Institute, said that the clinical trials system was largely delivering marginal benefits to patients at great cost.